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ABSTRACT: Calcitonin gene-related peptide (CGRP) binds
to the complex of the calcitonin receptor-like receptor (CLR)
with receptor activity-modifying protein 1 (RAMP1). How
CGRP interacts with the transmembrane domain (including
the extracellular loops) of this family B receptor remains
unclear. In this study, a photoaﬃnity cross-linker, p-azido L-
phenylalanine (azF), was incorporated into CLR, chieﬂy in
the second extracellular loop (ECL2) using genetic code
expansion and unnatural amino acid mutagenesis. The
method was optimized to ensure eﬃcient photolysis of azF
residues near the transmembrane bundle of the receptor. A CGRP analogue modiﬁed with ﬂuorescein at position 15 was used
for detection of ultraviolet-induced cross-linking. The methodology was veriﬁed by conﬁrming the known contacts of CGRP to
the extracellular domain of CLR. Within ECL2, the chief contacts were I284 on the loop itself and L291, at the top of the ﬁfth
transmembrane helix (TM5). Minor contacts were noted along the lip of ECL2 between S286 and L290 and also with M223 in
TM3 and F349 in TM6. Full length molecular models of the bound receptor complex suggest that CGRP sits at the top of the
TM bundle, with Thr6 of the peptide making contacts with L291 and H295. I284 is likely to contact Leu12 and Ala13 of CGRP,
and Leu16 of CGRP is at the ECL/extracellular domain boundary of CLR. The reduced potency, Emax, and aﬃnity of
[Leu16Ala]-human α CGRP are consistent with this model. Contacts between Thr6 of CGRP and H295 may be particularly
important for receptor activation.
Calcitonin gene-related peptide (CGRP) is an abundantsensory neuropeptide; it is known to be a very potent
vasodilator and is implicated in migraines. It is part of the
calcitonin superfamily of peptides that also includes
adrenomedullin, adrenomedullin 2/intermedin, and amylin.1,2
The peptides all bind to family B/secretin-like G protein-
coupled receptors, either the calcitonin receptor or the
calcitonin receptor-like receptor (CLR). However, for high-
aﬃnity binding for all of these ligands apart from calcitonin, it
is necessary for the receptor to form a complex with a second
transmembrane protein from the receptor activity-modifying
protein (RAMP) family with only three members. The CGRP
receptor is formed from CLR and RAMP1, although CGRP
will also bind with high aﬃnity to the complex of the calcitonin
receptor and RAMP1.1
The binding of endogenous peptide ligands to family B
GPCRs generally follows the two-domain model in which the
N-terminal tail of the peptide interacts with the trans-
membrane (TM) domain of the receptor whereas the C-
terminal tail binds to the extracellular domain (ECD) of the
receptor.3 Recently, a number of structures of full length family
B GPCRs have been published, namely, for the glucagon and
glucagon-like peptide 1 (GLP-1) receptors.4−8 The full length
calcitonin receptor has been visualized by cryo-electron
microscopy, but the ECD of the receptor was very ﬂexible
and so could not be resolved. The bound salmon calcitonin
peptide was also poorly resolved, and its binding mode was
reﬁned by only rigid body ﬁtting of the calcitonin receptor
ECD structure [Protein Data Bank (PDB) entry 5II0] and
conﬁrmed with data from mutagenesis.9 For the CGRP
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receptor, a crystal structure is available showing the C-terminal
tail of a CGRP analogue bound to the ECDs of CLR and
RAMP1.10 Extensive mutagenesis data that have allowed the
construction of models of how CGRP interacts with the TM
domain of the receptor are available.11−15 These studies have
implicated extracellular loop 2 (ECL2) of CLR as being
especially important for CGRP binding.12−14 However, direct
evidence of molecular contacts between the ligand and
receptor is lacking.
Photoaﬃnity cross-linking has long been used to map the
binding of ligands to receptors.16 Conventionally, a photo-
aﬃnity cross-linker is incorporated into the ligand; this then
requires extensive peptide mapping to identify the most likely
contact point on the receptor. With the use of genetic code
expansion and unnatural amino acid mutagenesis,17 it is now
possible to incorporate the photoaﬃnity cross-linker into the
receptor, thereby eliminating the need for peptide mapping or
sequencing to identify contact points on the receptor. This
general approach, known as targeted photo-cross-linking,18 has
been used to map ligand−receptor interactions in a number of
GPCRs, including the neurokinin NK-1 receptor,19 ghrelin
receptor,20 type 1 receptor for the corticotropin releasing
factor (CRF1R),21−23 and GLP-1 receptor.24 This has not yet
been extensively applied to a complex dimeric receptor, such as
the CGRP receptor. In the study presented here, we have
developed a modiﬁed targeted photo-cross-linking strategy to
study ECL2 of CLR and have identiﬁed two major contact
points for CGRP: I284 and L291.
■ MATERIALS AND METHODS
Materials. Human α CGRP was from Bachem (St. Helens,
U.K.). CGRP analogues were synthesized as indicated below.
Alpha Screen, LANCE cAMP assay kits, reagents, plates, and
125I-labeled human iodohistidyl10-α-CGRP were purchased
from PerkinElmer (Waltham, MA).
Peptide Synthesis. [Lys(5(6)-carboxyﬂuorescein)15]-α-
CGRP, [Leu12]-α-CGRP, and [Leu16]-α-CGRP were synthe-
sized by solid phase peptide synthesis using the Fmoc/tBu
method on a 0.1 mmol scale largely as described previously.25
Brieﬂy, Rink amide ChemMatrix resin (0.48 mmol/g) was
elongated using a PS3 (Protein Technologies, Tucson, AZ)
automated peptide synthesizer. The Fmoc group was removed
with 20% piperidine in dimethylformamide (DMF) (v/v) for 2
× 5 min, and the Fmoc amino acids were coupled for 20 min
using 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxide hexaﬂuorophosphate and N,N-diisopro-
pylethylamine. A pseudoproline, Fmoc-Leu-Ser[ψ-Me,MePro]
was used at position 16/17 to increase the synthetic
eﬃciency.26 To enable incorporation of the 5(6)-carboxy-
ﬂuorescein to a side chain amine, Leu15 was substituted with
Lys(Dde) [Dde = 1-(4,4-dimethyl-2,6-dioxacyclohexylidene)-
ethyl]. Boc-alanine was used as the N-terminal amino acid.
Following chain assembly, on-resin removal of the Dde
group on Lys15 was accomplished with 2% hydrazine hydrate in
DMF (v/v) for 2 × 3 min, and 5(6)-carboxyﬂuorescein was
coupled with N,N′-diisopropylcarbodiimide/1-hydroxybenzo-
triazole overnight. The resin was then treated with 20%
piperidine in DMF (v/v) for 4 × 5 min to remove excess 5(6)-
carboxyﬂuorescein.27 The crude peptide was cleaved from the
resin with concomitant removal of side chain protecting groups
with 94% triﬂuoroacetic acid, 1% triisopropylsilane, 2.5%
water, and 2.5% ethanedithiol (v/v/v/v) for 3 h, precipitated
with cold diethyl ether, isolated by centrifugation, dissolved in
50% aqueous acetonitrile containing 0.1% triﬂuoroacetic acid,
and lyophilized to aﬀord 228 mg of the crude peptide. The
crude ﬂuorescently labeled α-CGRP was analyzed by liquid
chromatography and mass spectrometry (calcd mass of
4165.33 Da, found mass of 4163.30 ± 0.9 Da) and then
puriﬁed by sample displacement chromatography28 on a C18
Gemini (Phenomenex) column (10 mm × 250 mm) at a ﬂow
rate of 5 mL/min at 50 °C to give 25.1 mg of pure linear
(unoxidized) [Lys(5(6)-carboxyﬂuorescein)15]-α-CGRP.
The linear peptide (25 mg) was dissolved in 0.1 M Tris-HCl
(pH 7.85) at a concentration of 1 mg/mL, and the oxidation
(disulﬁde formation) was allowed to proceed at room
temperature open to air. Monitoring by reverse phase high-
performance liquid chromatography (HPLC) indicated that
the reaction was complete after 5 h. The reaction mixture was
acidiﬁed to pH 2, diluted with water (60 mL), and puriﬁed by
semipreparative reverse phase HPLC using a C18 Gemini
column (10 mm × 250 mm) at a ﬂow rate of 5 mL/min at 50
°C and eluted using an appropriate gradient based on the
analytical HPLC proﬁle. Fractions containing the pure peptide
were identiﬁed by electrospray mass spectrometry and/or
HPLC, pooled, and lyophilized to give [Lys(5(6)-carboxy-
ﬂuorescein)15]-α-CGRP at >95% purity as judged by
integration of the HPLC chromatogram at 210 nm (calcd
mass of 4163.31 Da, found mass of 4162.20 ± 0.5 Da).
Unnatural Amino Acid Mutagenesis and Cross-Link-
ing Strategy. Unnatural amino acid mutagenesis was
performed in HEK293T cells as described previously,24,29
using Amber mutant human CLR, myc-tagged RAMP1,
suppressor tRNA, and azF aminoacyl tRNA synthetase but
with some modiﬁcations. HEK293T cells were seeded to a
density of 800000 cells per well (resulting in 70% cell
conﬂuence the next day) of a six-well plate. Twenty-four hours
after being seeded, the cells were transfected with a DNA
cocktail comprising 1 μg of mutated/WT receptor, 1 μg of
suppressor tRNA, and 0.5 μg of aminoacyl tRNA synthetase
using lipofectamine (Life Technologies catalog no. 18324-012)
as per the manufacturer’s instructions. Four hours post-
transfection, the medium was replaced with Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with 20%
(v/v) FBS and 1 mM azF, which itself was subsequently
replaced after 24 h with DMEM supplemented with 20% (v/v)
FBS and 0.5 mM azF. Cells were harvested after a further 24 h,
and the membrane fraction was isolated by centrifugation. The
membranes were incubated with the labeled peptide for 1 h at
room temperature. Once the incubation was complete, the
sample was split into two equal parts. One part was pipetted
into a quartz cuvette and exposed to 254 nm light for 1 h (an
exposure longer than that previously reported24), while the
other was wrapped in aluminum foil and also placed in the
light source. Heat was dissipated in both samples using silicone
tubing inserted into the cuvette that was ﬂushed with ice-cold
water. Cross-linking was performed in a UVP cross-linker
(Analytik-Jena AG) at an energy of 100 μJ/cm,2 with the
sample approximately 10 cm from the light source. Both the
cross-linked samples and the control samples were pelleted by
centrifugation, washed using phosphate-buﬀered saline, and
solubilized using dodecyl maltoside for 4 h. Post-solubilization,
the samples were centrifuged at 30000g for 30 min, after which
150 μL of the soluble fraction was pipetted into a well of a 96-
well plate and read using a Mithras LB 940 instrument
(Berthould). The cross-linked and control samples were
compared to determine the degree of peptide labeling.
Biochemistry Article
DOI: 10.1021/acs.biochem.8b00502
Biochemistry 2018, 57, 4915−4922
4916
Tyrosine Mutagenesis. Individual amino acids in human
HA-tagged CLR were mutated to tyrosine as described
previously.11,12,14
cAMP Production. Human HA-tagged CLR (WT or
mutant) and myc-tagged RAMP1 were transfected into
HEK293T or HEK293S cells, stimulated with human α-
CGRP or synthetic peptides, and cAMP accumulation was
measured via Alpha Screen or LANCE as previously
described.11,13,30
Radioligand Binding. Competition radioligand binding
assays were performed on HEK293S membranes using 125I-
labeled human α-CGRP. HEK293S cells were grown in 15 cm
dishes, and each dish was transfected with 30 μg of human HA-
tagged CLR and 30 μg of myc-tagged RAMP1 using
polyethylenimine (PEI) as described previously.13 Forty-eight
hours after transfection, membranes were isolated by
homogenizing cells followed by centrifugation at 100000g for
1 h at 4 °C, and membranes were resuspended and stored at
−80 °C. The binding assay was performed essentially as
described previously31 except the membranes were incubated
with labeled and unlabeled peptides for 1 h at room
temperature.
Data Analysis. Concentration response curves were ﬁtted
to a three-parameter logistic equation to obtain Emax, pEC50,
and basal responses. The Hill coeﬃcient was constrained to
unity. Curve ﬁtting was performed with GraphPad Prism
version 7, as described previously.13 For photoaﬃnity cross-
linking, paired Student’s t tests were used to assess if the total
cross-linking for each mutant was statistically diﬀerent from the
nonspeciﬁc cross-linking, accepting signiﬁcance at a P < 0.05
level.
Molecular Modeling. Homology models of the active
CLR were generated using Modeler32 utilizing the recently
determined cryo-electron microscope structures of the
activated GLP-1 and calcitonin receptors (PDB entries 5VAI
and 5UZ7, respectively).8,9 One thousand models combining
homology-based restraints from both templates (>2 Å root-
mean-square deviation between models) were generated by
Modeler using the default method. The transmembrane and
loop regions of the Modeler-based structures were further
reﬁned and ranked using the membrane relax module of
ROSETTA.33 The reﬁned models were clustered, and the best
model was chosen on the basis of the largest cluster with the
lowest ROSETTA membrane score.
The peptide was initially ab initio folded using an in-house
script with a disulﬁde bond constraining Cys2 and Cys7 of the
peptide. Regions of secondary structure34 were also imposed
on the ab initio simulation. The best scoring folded peptide was
docked on the basis of the FlexPepDock module of
ROSETTA; 10000 docking solutions between the peptide
and receptor were generated. The FlexPepDock docked
solutions were ﬁltered in two stages. The docked solutions
were initially ﬁltered using analogous contact restraints (cutoﬀ
of 5 Å) as observed in the 4RWG crystal structure.9 These
results were further ﬁltered by keeping any solution in which
both Ile284 and Leu291 were within 5 Å of any atom of the
docked CGRP ligand. The ﬁltered results (737 docked poses)
were then further reﬁned using the membrane relax module
also found in the ROSETTA suite of software. The middle
structure of the largest, lowest-energy cluster was chosen for
further analysis.
Replica exchange Monte Carlo simulations as implemented
in Hippo35 were used explore the conformational space of the
ROSETTA-reﬁned model. Sixteen replicas were simulated over
the temperature range of 300−500 K following a Boltzmann
distribution in a 30 Å implicit membrane. Other variables were
kept as the default settings. The trajectory was visualized using
Visual Molecular Dynamics.36
■ RESULTS
Activity of [Lys(5(6)-carboxyﬂuorescein)15] Human α-
CGRP (15-Fluo CGRP). To identify cross-linking to CLR, a
ﬂuorescent CGRP agonist was required. On the basis of
previously published structure−activity data,37 supported by
molecular modeling,11,38 we reasoned that it should be possible
to modify CGRP at position 15 while retaining agonist activity.
The native Leu at this residue was replaced by Lys and
derivatized with 5(6)-carboxyﬂuorescein. The resulting ana-
logue was evaluated for its ability to stimulate cAMP
production via the CGRP receptor. While it had reduced
potency, it was a full agonist (Figure 1), suggesting that this
modiﬁcation did not greatly aﬀect the functional properties of
the ligand
Conﬁrmation of the Cross-Linking Strategy. Prelimi-
nary experiments indicated that optimal speciﬁc cross-linking
was obtained following a 1 h exposure to ultraviolet (UV) light.
The availability of a crystal structure showing the binding of a
modiﬁed CGRP analogue to the extracellular domain of the
CGRP receptor10 provided a system for evaluating our
methodology. A series of azF mutants was constructed in
which residues within 5 Å of or more than 7 Å from the bound
CGRP analogue were substituted. There was excellent
agreement between the ability of the mutants to cross-link to
CGRP and their distances from the bound CGRP analogue in
the crystal structure (Figure 2).
Cross-Linking by Residues in ECL2. A scan was then
performed on ECL2 of CLR and its ﬂanking regions from
H270 to Y292, excluding C282, which is involved in a
conserved disulﬁde bond with C212 at the extracellular end of
TM3. The data suggest that major points of attachment for 15-
Fluo CGRP are I284 and L291, with much weaker although
signiﬁcant labeling in a number of other positions at the distal
end of the loop (Figure 3). There was virtually no speciﬁc
labeling at any position in the loop proximal to D280. It is
possible that a lack of labeling might simply reﬂect the fact that
the receptor is nonfunctional when substituted with azF. To
test this, a Tyr scan of the residues mutated to azF was
performed, excluding the native tyrosines at positions 277 and
278 (Figure 4). A Tyr rather than an azF scan was performed
Figure 1. cAMP production on HEK293T cells transfected with CLR
and RAMP1 and exposed to CGRP or 15-Fluo CGRP for 15 min.
Values are means ± the standard error of the mean (SEM); n = 3
independent experiments.
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because the modiﬁed aminoacyl tRNA synthetase used to
incorporate azF will also accept Tyr, albeit at lower eﬃciency,
resulting in a mixed population of receptors potentially with
one of two diﬀerent residues at the same site.24 Tyr is
structurally the closest natural amino acid to azF. The results
showed that all the mutants assessed should still be able to
interact with 15-Fluo CGRP at 100 nM, the concentration
used in our cross-linking experiments, as the Tyr mutants
retained a good sensitivity to CGRP.
Role of TM3 and TM6. The current cross-linking data and
previous mutation studies have indicated that ECL2 and the
ﬁrst turn of TM5 are important in forming the binding site for
CGRP. We extended the use of our cross-linking method to
address the role of other parts of the receptor. M223 (TM3)
and F349 (TM6) were mutated to azF. These residues are
likely to face into the TM bundle of CLR but are
approximately two helical turns deeper into the TM bundle
than L291 is (Figure 6). Thus, they provide insight into how
far CGRP penetrates into the TM core of CLR. The speciﬁc
cross-linking seen with both of these residues was comparable
with that of S286 (Figure 5), which appears to act as a minor
contact in ECL2 (Figure 3), although we cannot exclude a
lower cross-linking eﬃciency due to poor photolysis of residues
deep in the TM bundle. It seems likely that M223 and F349
are at the base of the binding pocket for CGRP.
Molecular Modeling of Bound CGRP. Our modeling
suggests that CGRP extends down as far as H295, in TM5.
I284 is close to Leu12 and Ala13 of CGRP, and L291 is adjacent
to Thr6 of CGRP (Figure 6). Leu16 of CGRP is the most
proximal residue of the bound CGRP to make potential
contact with the ECLs. It is close to I284 and V198 (in ECL1)
but is also in the proximity of I32 of the ECD, perhaps making
contact with both ECLs and the ECD of CLR.
Activity of [Leu12Ala]- and [Leu16Ala]-Human α-CGRP.
To further test our proposed mode of binding, we investigated
the ability of [Leu12Ala]- and [Leu16Ala]-human α-CGRP to
stimulate cAMP. Both analogues showed substantial reductions
in potency and Emax, with [Leu
16Ala]-human α-CGRP showing
the largest eﬀects (Figure 7). This result was conﬁrmed in a
radioligand binding assay, in which [Leu16Ala]-human α-
CGRP also showed a substantial reduction in aﬃnity.
Figure 2. Fluorescence of solubilized HEK293T cell membranes from
cells transfected with RAMP1 and CLR containing azF substitutions
at the indicated residues. Membranes were exposed to 15-Fluo CGRP
in the presence or absence of UV light. D94, H114, W121, and N128
are all within 5 Å of bound CGRP;10 other residues are 7−10 Å away.
Values are means ± SEM; n = 3. *P < 0.05, and **P < 0.01; values of
total labeling that are signiﬁcantly diﬀerent from the nonspeciﬁc
values in the paired control samples, i.e., in the absence of UV light.
Figure 3. Fluorescence of solubilized HEK293T cell membranes from
cells transfected with RAMP1 and CLR containing azF substitutions
at the indicated residues. Membranes were exposed to 15-Fluo CGRP
in the presence or absence of UV light. The values are the speciﬁc
labeling, following subtraction of the nonspeciﬁc from total bound
ﬂuorescence. Values are means ± SEM; n = 3−6. *P < 0.05; values for
which total labeling is signiﬁcantly diﬀerent from the nonspeciﬁc
values in the paired control samples, i.e., in the absence of UV light.
Nonspeciﬁc labeling ranged from 2247 to 5759 AU.
Figure 4. Tyrosine scan of ECL2. Potency of human α-CGRP at
stimulating cAMP production in HEK293T cells transfected with
CLR (WT or mutants) and RAMP1. Values are means ± SEM; n = 3.
Figure 5. Fluorescence of solubilized HEK293T cell membranes from
cells transfected with RAMP1 and CLR containing azF substitutions
at the indicated residues. Membranes were exposed to 15-Fluo CGRP
in the presence or absence of UV light. Values are means ± SEM; n =
3. *P < 0.05; values of total labeling signiﬁcantly diﬀerent from the
nonspeciﬁc values in the paired control samples, i.e., in the absence of
UV light.
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■ DISCUSSION
We have used unnatural amino acid mutagenesis to map key
residues in and adjacent to ECL2 of CLR that contribute to
the binding of CGRP. The data suggest that I284 and L291
make contacts in the vicinity of Thr6 and Leu12 of bound
CGRP. This binding orientation is consistent with the
modeled position of calcitonin in the cryo-electron microscopy
structure of the calcitonin receptor.9
A number of the residues that we have identiﬁed in this
study as contributing to the binding of CGRP have been
previously identiﬁed as being important for CGRP production
of cAMP, based on mutagenesis. We predicted that I284 could
interact with one or more CGRP residues C-terminal to the 2−
7 disulﬁde-bonded loop of the peptide, conventionally
considered to be the mediator of receptor activation.13
However, using an alanine scan, we have previously found
that changes to Val8 and Thr9 of CGRP can alter its eﬃcacy.25
Our current model suggests that Val8 is adjacent to H194 in
TM2 and Thr9 is in the proximity of the backbone of ECL2.
Our study further extends this by demonstrating that Leu16 in
CGRP can inﬂuence eﬃcacy, potentially by contacting I32 in
the ECD of CLR. Furthermore, we have observed during a
replica exchange Monte Carlo simulation of the bound CGRP
(to investigate dynamic stability), L16 periodically interacts
with V198 (ECL1) and I284 of CLR. V198 and I32 have both
been shown to be important for cAMP production by
CGRP.40,41 These observations suggest how CGRP residues
outside of the classic 1−7 “activation” domain of the peptide
can inﬂuence eﬃcacy; we speculate that Leu16 may be
particularly important in interacting with both the ECLs and
ECD of CLR. It may therefore be possible to develop
truncated analogues that retain agonist activity by interacting
with the upper regions of the TM bundle and ECLs, as has
been done for GLP-1.42
Within the 1−7 region of CGRP, our previous structure−
activity work indicated that Thr6 was essential for agonism. In
fact, this residue is absolutely conserved in all members of the
calcitonin family of peptides.25,34 In our model, Thr6 of CGRP
is close to not only L291 of TM5 but also H295 a turn lower.
Previous mutagenesis has shown that H295 is important for
the activation of all CLR/RAMP complexes with both CGRP
and adrenomedullin;11 its equivalent is also important for
agonism by calcitonin in the calcitonin receptor.9 Molecular
dynamics simulations indicated that H295, at the top of TM5,
controls interhelical contacts among TM3, TM5, TM6, and
TM7 of CLR. A rotation of this residue caused helix sliding
and tilting that opened the G protein binding pocket.11
Residues deeper in the receptor that are important for receptor
activation such as E34811 would seem unlikely to be signiﬁcant
ligand contacts, unless they are connected by bound water
molecules.
Although I284 and L291 were the main contacts revealed in
this study, it is interesting to note that there were a range of
minor contacts in the distal part of ECL2. The pattern here
was that every other residue between I284 and L290 appeared
as contacts. Interestingly, our previous mutagenesis and
modeling have suggested that this forms a short stretch of β-
strand, along the rim of the cavity between TM4 and TM5.12
This secondary structure element is consistent with the
labeling pattern.
Figure 6. Molecular model of the CLR (brown ribbon)/RAMP1
(blue ribbon; TM region omitted for the sake of clarity) complex with
bound CGRP (pink ribbon). (A) Detail of predicted interactions of
CGRP with I284 and L291. (B) Predicted position of bound CGRP
with residues on the periphery of the binding site. CLR residues
shown in space-ﬁlling mode; CGRP residues colored green. The
models can be viewed online using Molecule Viewer39 at https://bit.
ly/2FnQAHp (recommended browsers are Google Chrome in
incognito mode or Firefox). (C) Full length structure of the CLR
complex. The positions of TM5 and helix 8 are highlighted to aid
orientation.
Figure 7. Comparison of the ability of [Leu12Ala]- and [Leu16Ala]-
human α-CGRP (A) to stimulate cAMP in HEK293S cells transfected
with HA-CLR and myc-RAMP1 or (B) to displace [125I]CGRP at the
CGRP receptor. Values are means ± SEM; n = 3 or 4.
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In eight of 15 of the human family B GPCRs, the equivalent
of I284 is glutamic or aspartic acid; in three additional
receptors, it is threonine. Only in CLR, the calcitonin receptor
(leucine), and the corticotrophin receptors (phenylalanine) is
the corresponding residue hydrophobic. Thus, within family B
GPCRs, this residue may be important in ligand speciﬁcity; it
faces into the core of the receptor where it can be resolved in
structures. In the calcitonin receptor, the equivalent residue is
important for the binding of human and porcine but not
salmon calcitonin, indicating how similar ligands can diﬀer-
entially interact with residues within their binding pockets.43
The absence of labeling for W283 is noteworthy as this residue
is highly conserved in family B GPCRs and mutation may
show deleterious eﬀects.44,45 Its side chain orientation is
variable in the current family B GPCR structures, either facing
into the core in the calcitonin and glucagon receptor structures
or inserting between TM3 and TM4 in other structures.4,5,9,46
These data suggest that W283 does not contact the peptide,
indicating it is most likely to be inserted between TM3 and
TM4 (Figure 6B).
The techniques described in this paper may be applied to
other receptors. While previously the method has been applied
to the GLP-1 receptor,24 our experience is that signiﬁcant
reﬁnement is required. In the study presented here, it was
necessary to illuminate the receptor for 1 h to obtain cross-
linking, rather than for the 5 min used in the GLP-1 study.
This diﬀerence may reﬂect the fact that the GLP-1 study was
focused on the extracellular domain of the receptor; greater
exposure times may be necessary for residues within the
membrane domain. In studies of CRF1R, where trans-
membrane residues were also targeted, illumination was
performed for 20−40 min.21,22 Thus, investigators should
optimize labeling conditions to ensure their protocols are
maximally eﬀective. The cross-linking eﬃciency will also
depend on the power of the UV source and the distance of
the sample from the light, which are likely to vary between
laboratories.
In conclusion, this study suggests that CGRP binds to a
pocket formed by the ECLs of CLR, penetrating approximately
two turns into the TM region. Direct contacts with residues
here and in the ECLs form the basis of the agonist-induced
conformational shift in CLR during receptor activation.
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